On November 13, WUXI BIO fell 3.11% in Regular Trading, trading at HK$47.42, with turnover of HK$344 million.
The latest market information indicates the pullback is more closely associated with broader weakness across Life Sciences Tools & Services names, while the positive impact from the company’s previously announced Fresenius collaboration and supportive broker expectations appears to have cooled after being repeatedly traded.
Background context shows WUXI BIO previously entered a 10-year exclusive development agreement covering up to 37 biosimilar candidates with Fresenius, described as the largest such development deal announced in the biosimilars industry. Separately, Citi placed the stock on a 90-day positive catalyst watchlist, citing potential for a fourth-quarter guidance upgrade, while UBS maintained a Buy rating with a HK$62 target price. Sector trading was weak as well, with GENSCRIPT B-1K falling 3.45%, WUXI APPTEC falling 2.09%, WUXI XDC falling 2.57%, INSILICO falling 1.84%, and XTALPI falling 2.31%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments